Evidence map›Paper›PMID 25157105›Full record

ArticleThe Journal of biological chemistry2014

Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.

Takashi Mori, Naoki Koyama, Tatsuya Segawa, Masahiro Maeda, Nobuhiro Maruyama, Noriaki Kinoshita, Huayan Hou, Jun Tan, Terrence Town

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Pretreatment with Methylene Blue Protects Against Acute Seizure and Oxidative Stress in a Kainic Acid-Induced Status Epilepticus Model.Medical science monitor : international medical journal of experimental and clinical research · 2021
    Article
  5. Effect of Methylene Blue on White Matter Injury after Ischemic Stroke.Oxidative medicine and cellular longevity · 2021
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery.SLAS discovery : advancing life sciences R & D · 2017
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Takashi MoriDepartments of Biomedical Sciences and Saitama Medical Center and University, Kawagoe, Saitama 350-8550, Japan; Departments of Pathology, Saitama Medical Center and University, Kawagoe, Saitama 350-8550, Japan,. Electronic address: t_mori@saitama-med.ac.jp.
Naoki KoyamaDepartments of Biomedical Sciences and Saitama Medical Center and University, Kawagoe, Saitama 350-8550, Japan.
Tatsuya SegawaImmuno-Biological Laboratories Co., Ltd., Fujioka, Gunma 375-0005, Japan.
Masahiro MaedaImmuno-Biological Laboratories Co., Ltd., Fujioka, Gunma 375-0005, Japan.
Nobuhiro MaruyamaImmuno-Biological Laboratories Co., Ltd., Fujioka, Gunma 375-0005, Japan.
Noriaki KinoshitaImmuno-Biological Laboratories Co., Ltd., Fujioka, Gunma 375-0005, Japan.
Huayan HouRashid Laboratory for Developmental Neurobiology, Silver Child Development Center and University of South Florida, Tampa, Florida 33613.
Jun TanRashid Laboratory for Developmental Neurobiology, Silver Child Development Center and University of South Florida, Tampa, Florida 33613; Neuroimmunology Laboratory, Department of Psychiatry and Behavioral Neurosciences, Morsoni College of Medicine, University of South Florida, Tampa, Florida 33613, and.
Terrence TownZilkha Neurogenetic Institute, Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90089-2821. Electronic address: ttown@usc.edu.
Medical & Biological Laboratories (Japan) · JPSocial Insurance Saitama Chuo Hospital · JPUniversity of South Florida · USUniversity of Southern California · US

Funding

Peripheral TGF-beta Pathway Inhibitor Therapy in Alzheimer's RatsR01NS076794 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHANG, KAREN T, CHEN, JEANNIE · 2011 to 2021
$4.9M
NINDS NIH HHS 1R01NS076794-01NINDS NIH HHS R01 NS076794
6 · The paper itself

Abstract

Amyloid precursor protein (APP) proteolysis is required for production of amyloid-β (Aβ) peptides that comprise β-amyloid plaques in the brains of patients with Alzheimer disease (AD). Here, we tested whether the experimental agent methylene blue (MB), used for treatment of methemoglobinemia, might improve AD-like pathology and behavioral deficits. We orally administered MB to the aged transgenic PSAPP mouse model of cerebral amyloidosis and evaluated cognitive function and cerebral amyloid pathology. Beginning at 15 months of age, animals were gavaged with MB (3 mg/kg) or vehicle once daily for 3 months. MB treatment significantly prevented transgene-associated behavioral impairment, including hyperactivity, decreased object recognition, and defective spatial working and reference memory, but it did not alter nontransgenic mouse behavior. Moreover, brain parenchymal and cerebral vascular β-amyloid deposits as well as levels of various Aβ species, including oligomers, were mitigated in MB-treated PSAPP mice. These effects occurred with inhibition of amyloidogenic APP proteolysis. Specifically, β-carboxyl-terminal APP fragment and β-site APP cleaving enzyme 1 protein expression and activity were attenuated. Additionally, treatment of Chinese hamster ovary cells overexpressing human wild-type APP with MB significantly decreased Aβ production and amyloidogenic APP proteolysis. These results underscore the potential for oral MB treatment against AD-related cerebral amyloidosis by modulating the amyloidogenic pathway.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAmyloidosisAmyloid Precursor Protein SecretasesAnimalsBrain DiseasesCerebral CortexCHO CellsCognitionCricetinaeCricetulusDrug Evaluation, PreclinicalHumansMaleMaze LearningMethylene BlueAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesMethylene BlueAlzheimer DiseaseAmyloidAmyloid Precursor Protein (APP)Animal ModelAnti-amyloidogenicMethylene BlueSecretaseTransgenic Mouseβ-Secretase

Identifiers

PMID25157105
PMCPMC4215215
OpenAlexW2030053236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.